Dissociable effects of alzheimer disease and white matter hyperintensities on brain metabolism

Thaddeus J. Haight, Susan M. Landau, Owen Carmichael, Christopher Schwarz, Charles DeCarli, William J. Jagust

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

IMPORTANCE Cerebrovascular disease and Alzheimer disease (AD) frequently co-occur and seem to act through different pathways in producing dementia. OBJECTIVE To examine cerebrovascular disease and AD markers in relation to brain glucose metabolism in patients with mild cognitive impairment. DESIGN AND SETTING Cohort study among the Alzheimer Disease Neuroimaging Initiative clinical sites in the United States and Canada. PARTICIPANTS Two hundred three patients having amnestic mild cognitive impairment (74 of whom converted to AD) with serial imaging during a 3-year follow-up period. MAIN OUTCOMES AND MEASURES Quantified white matter hyperintensities (WMHs) represented cerebrovascular disease, and cerebrospinal fluid β-amyloid represented AD pathology. Brain glucose metabolism in temporoparietal and frontal brain regions was measured using positron emission tomography with fluorodeoxyglucose F18. RESULTS In converters, greater WMHs were associated with decreased frontal metabolism (-0.048; 95%CI, -0.067 to -0.029) but not temporoparietal metabolism (0.010; 95%CI, -0.010 to 0.030). Greater cerebrospinal fluid β-amyloid (per 10-pg/mL increase) was associated with increased temporoparietal metabolism (0.005; 95%CI, 0.000-0.010) but not frontal metabolism (0.002; 95%CI, -0.004 to 0.007) in the same patients. In nonconverters, similar relationships were observed except for a positive association of greater WMHs with increased temporoparietal metabolism (0.051; 95%CI, 0.027-0.076). CONCLUSIONS AND RELEVANCE The dissociation of WMHs and cerebrospinal fluid β-amyloid in relation to regional glucose metabolism suggests that these pathologic conditions operate through different and independent pathways in AD that reflect dysfunction in different brain systems. The positive association of greater WMHs with temporoparietal metabolism suggests that these pathologic processes do not co-occur in nonconverters.

Original languageEnglish (US)
Pages (from-to)1039-1045
Number of pages7
JournalJAMA neurology
Volume70
Issue number8
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Alzheimer Disease
Brain
Cerebrovascular Disorders
Amyloid
Cerebrospinal Fluid
Glucose
White Matter
Fluorodeoxyglucose F18
Pathologic Processes
Neuroimaging
Positron-Emission Tomography
Canada
Dementia
Cohort Studies
Pathology

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Dissociable effects of alzheimer disease and white matter hyperintensities on brain metabolism. / Haight, Thaddeus J.; Landau, Susan M.; Carmichael, Owen; Schwarz, Christopher; DeCarli, Charles; Jagust, William J.

In: JAMA neurology, Vol. 70, No. 8, 01.01.2013, p. 1039-1045.

Research output: Contribution to journalArticle

Haight, Thaddeus J. ; Landau, Susan M. ; Carmichael, Owen ; Schwarz, Christopher ; DeCarli, Charles ; Jagust, William J. / Dissociable effects of alzheimer disease and white matter hyperintensities on brain metabolism. In: JAMA neurology. 2013 ; Vol. 70, No. 8. pp. 1039-1045.
@article{af1c24c5f9f24e539c45864e2b0e4383,
title = "Dissociable effects of alzheimer disease and white matter hyperintensities on brain metabolism",
abstract = "IMPORTANCE Cerebrovascular disease and Alzheimer disease (AD) frequently co-occur and seem to act through different pathways in producing dementia. OBJECTIVE To examine cerebrovascular disease and AD markers in relation to brain glucose metabolism in patients with mild cognitive impairment. DESIGN AND SETTING Cohort study among the Alzheimer Disease Neuroimaging Initiative clinical sites in the United States and Canada. PARTICIPANTS Two hundred three patients having amnestic mild cognitive impairment (74 of whom converted to AD) with serial imaging during a 3-year follow-up period. MAIN OUTCOMES AND MEASURES Quantified white matter hyperintensities (WMHs) represented cerebrovascular disease, and cerebrospinal fluid β-amyloid represented AD pathology. Brain glucose metabolism in temporoparietal and frontal brain regions was measured using positron emission tomography with fluorodeoxyglucose F18. RESULTS In converters, greater WMHs were associated with decreased frontal metabolism (-0.048; 95{\%}CI, -0.067 to -0.029) but not temporoparietal metabolism (0.010; 95{\%}CI, -0.010 to 0.030). Greater cerebrospinal fluid β-amyloid (per 10-pg/mL increase) was associated with increased temporoparietal metabolism (0.005; 95{\%}CI, 0.000-0.010) but not frontal metabolism (0.002; 95{\%}CI, -0.004 to 0.007) in the same patients. In nonconverters, similar relationships were observed except for a positive association of greater WMHs with increased temporoparietal metabolism (0.051; 95{\%}CI, 0.027-0.076). CONCLUSIONS AND RELEVANCE The dissociation of WMHs and cerebrospinal fluid β-amyloid in relation to regional glucose metabolism suggests that these pathologic conditions operate through different and independent pathways in AD that reflect dysfunction in different brain systems. The positive association of greater WMHs with temporoparietal metabolism suggests that these pathologic processes do not co-occur in nonconverters.",
author = "Haight, {Thaddeus J.} and Landau, {Susan M.} and Owen Carmichael and Christopher Schwarz and Charles DeCarli and Jagust, {William J.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1001/jamaneurol.2013.1878",
language = "English (US)",
volume = "70",
pages = "1039--1045",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Dissociable effects of alzheimer disease and white matter hyperintensities on brain metabolism

AU - Haight, Thaddeus J.

AU - Landau, Susan M.

AU - Carmichael, Owen

AU - Schwarz, Christopher

AU - DeCarli, Charles

AU - Jagust, William J.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - IMPORTANCE Cerebrovascular disease and Alzheimer disease (AD) frequently co-occur and seem to act through different pathways in producing dementia. OBJECTIVE To examine cerebrovascular disease and AD markers in relation to brain glucose metabolism in patients with mild cognitive impairment. DESIGN AND SETTING Cohort study among the Alzheimer Disease Neuroimaging Initiative clinical sites in the United States and Canada. PARTICIPANTS Two hundred three patients having amnestic mild cognitive impairment (74 of whom converted to AD) with serial imaging during a 3-year follow-up period. MAIN OUTCOMES AND MEASURES Quantified white matter hyperintensities (WMHs) represented cerebrovascular disease, and cerebrospinal fluid β-amyloid represented AD pathology. Brain glucose metabolism in temporoparietal and frontal brain regions was measured using positron emission tomography with fluorodeoxyglucose F18. RESULTS In converters, greater WMHs were associated with decreased frontal metabolism (-0.048; 95%CI, -0.067 to -0.029) but not temporoparietal metabolism (0.010; 95%CI, -0.010 to 0.030). Greater cerebrospinal fluid β-amyloid (per 10-pg/mL increase) was associated with increased temporoparietal metabolism (0.005; 95%CI, 0.000-0.010) but not frontal metabolism (0.002; 95%CI, -0.004 to 0.007) in the same patients. In nonconverters, similar relationships were observed except for a positive association of greater WMHs with increased temporoparietal metabolism (0.051; 95%CI, 0.027-0.076). CONCLUSIONS AND RELEVANCE The dissociation of WMHs and cerebrospinal fluid β-amyloid in relation to regional glucose metabolism suggests that these pathologic conditions operate through different and independent pathways in AD that reflect dysfunction in different brain systems. The positive association of greater WMHs with temporoparietal metabolism suggests that these pathologic processes do not co-occur in nonconverters.

AB - IMPORTANCE Cerebrovascular disease and Alzheimer disease (AD) frequently co-occur and seem to act through different pathways in producing dementia. OBJECTIVE To examine cerebrovascular disease and AD markers in relation to brain glucose metabolism in patients with mild cognitive impairment. DESIGN AND SETTING Cohort study among the Alzheimer Disease Neuroimaging Initiative clinical sites in the United States and Canada. PARTICIPANTS Two hundred three patients having amnestic mild cognitive impairment (74 of whom converted to AD) with serial imaging during a 3-year follow-up period. MAIN OUTCOMES AND MEASURES Quantified white matter hyperintensities (WMHs) represented cerebrovascular disease, and cerebrospinal fluid β-amyloid represented AD pathology. Brain glucose metabolism in temporoparietal and frontal brain regions was measured using positron emission tomography with fluorodeoxyglucose F18. RESULTS In converters, greater WMHs were associated with decreased frontal metabolism (-0.048; 95%CI, -0.067 to -0.029) but not temporoparietal metabolism (0.010; 95%CI, -0.010 to 0.030). Greater cerebrospinal fluid β-amyloid (per 10-pg/mL increase) was associated with increased temporoparietal metabolism (0.005; 95%CI, 0.000-0.010) but not frontal metabolism (0.002; 95%CI, -0.004 to 0.007) in the same patients. In nonconverters, similar relationships were observed except for a positive association of greater WMHs with increased temporoparietal metabolism (0.051; 95%CI, 0.027-0.076). CONCLUSIONS AND RELEVANCE The dissociation of WMHs and cerebrospinal fluid β-amyloid in relation to regional glucose metabolism suggests that these pathologic conditions operate through different and independent pathways in AD that reflect dysfunction in different brain systems. The positive association of greater WMHs with temporoparietal metabolism suggests that these pathologic processes do not co-occur in nonconverters.

UR - http://www.scopus.com/inward/record.url?scp=84882395407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882395407&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2013.1878

DO - 10.1001/jamaneurol.2013.1878

M3 - Article

C2 - 23779022

AN - SCOPUS:84882395407

VL - 70

SP - 1039

EP - 1045

JO - JAMA Neurology

JF - JAMA Neurology

SN - 2168-6149

IS - 8

ER -